```html

Neutrophilic Dermatoses (e.g., Sweet’s Syndrome)

Overview

Neutrophilic dermatoses are a group of skin disorders characterized by an abnormal accumulation of neutrophils (a type of white blood cell) in the skin without an infectious cause. The most well‑known entity in this group is Sweet’s syndrome (acute febrile neutrophilic dermatosis). Other related conditions include pyoderma gangrenosum, subcorneal pustular dermatosis, and erythema elevatum diutinum.

Who it affects

• Adults: peak incidence between 30–60 years.
• Women are affected about 2–3 times more often than men.
• Can occur in children, but this is rare (<5 % of cases).

Prevalence

• Sweet’s syndrome has an estimated incidence of 2–4 cases per million persons per year in the United States.<sup>[1] Mayo Clinic</sup>
• Overall neutrophilic dermatoses are uncommon, accounting for < 0.1 % of dermatology outpatient visits.<sup>[2] Cleveland Clinic</sup>

Symptoms

Symptoms can appear suddenly (often within hours to days) and may involve one or many areas of the body.

Skin Manifestations

• Tender, erythematous plaques or nodules – most classic sign; usually bright red, sometimes violaceous, and exquisitely painful.
• Rapid onset – lesions often appear over a few days and may coalesce into larger plaques.
• Location – frequently on the neck, face, upper trunk, and arms; can affect lower extremities or mucous membranes.
• Edema (swelling) surrounding lesions.
• Vesicles or pustules – may develop on top of plaques in some patients.
• Burning or stinging sensation – often more intense than the visible redness would suggest.

Systemic Symptoms

• Fever (≥38 °C/100.4 °F) – present in up to 80 % of cases.
• Generalized malaise, fatigue, and arthralgia.
• Headache or myalgia.
• Leukocytosis (elevated white‑blood‑cell count, typically >10 × 10⁹/L) with neutrophil predominance.

Associated Findings in Specific Subtypes

• Pyoderma gangrenosum – painful ulcers with undermined edges.
• Subcorneal pustular dermatosis – superficial pustules that coalesce into annular plaques.
• Erythema elevatum diutinum – firm, reddish‑brown nodules on extensor surfaces.

Causes and Risk Factors

Neutrophilic dermatoses are considered hypersensitivity reactions; the exact trigger is often unknown (idiopathic), but several associations have been identified.

Underlying Medical Conditions

• Hematologic malignancies – especially acute myeloid leukemia, myelodysplastic syndromes, and lymphoma (≈20 % of Sweet’s cases).<sup>[3] NIH</sup>
• Solid tumors – breast, gastrointestinal, and genitourinary cancers have been reported.
• Autoimmune diseases – inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus.
• Infections – upper‑respiratory, urinary, or gastrointestinal infections can precede onset.
• Pregnancy – rare but documented cases.

Medications

Drugs that have been implicated include:

• Granulocyte colony‑stimulating factor (G‑CSF)
• All‑trans retinoic acid (ATRA)
• Non‑steroidal anti‑inflammatory drugs (NSAIDs)
• Antibiotics such as trimethoprim‑sulfamethoxazole

Other Risk Factors

• Recent upper respiratory or gastrointestinal infection (within 2 weeks).
• Vaccination – isolated case reports after influenza or COVID‑19 vaccines; causality not established.
• Genetic predisposition – no definitive gene has been identified, but family clustering is reported in rare cases.

Diagnosis

Because the presentation can mimic infection, vasculitis, or other dermatoses, a systematic approach is essential.

Clinical Evaluation

• Detailed history (onset, systemic symptoms, medication exposure, underlying disease).
• Full skin examination – note distribution, morphology, and tenderness.
• Assessment for systemic involvement (fever, joint pain, organ‑specific signs).

Laboratory Tests

• Complete blood count – typically shows neutrophilic leukocytosis.
• Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) – often markedly elevated.
• Serology for infections (e.g., streptococcal, hepatitis, HIV) if indicated.
• Autoimmune panel (ANA, ANCA) when an autoimmune cause is suspected.

Skin Biopsy (Gold Standard)

A punch or excisional biopsy provides definitive diagnosis.

1. Histology: dense neutrophilic infiltrate in the dermis without vasculitis; edema of the papillary dermis ( “edema with a sea of neutrophils”).
2. Absence of infection on special stains (Gram, PAS, acid‑fast) helps exclude bacterial or fungal causes.
3. Immunofluorescence is usually negative, differentiating it from leukocytoclastic vasculitis.

Additional Imaging (if needed)

• Chest X‑ray or CT to rule out underlying malignancy when clinical suspicion is high.
• PET‑CT may be ordered if a paraneoplastic process is suspected.

Treatment Options

Treatment targets the inflammatory cascade and any underlying trigger. Therapy is usually initiated promptly because lesions improve dramatically within days of effective treatment.

First‑Line Systemic Therapy

• Systemic corticosteroids – Prednisone 0.5–1 mg/kg/day (usually 30–60 mg) is the cornerstone. Rapid symptom relief (often within 24–48 h). Taper over 4–6 weeks to prevent relapse.

Corticosteroid‑Sparing Agents

Used for recurrent disease, steroid intolerance, or when underlying disease requires long‑term therapy.

• Dapsone – 50–100 mg daily; monitor for hemolysis, especially in G6PD‑deficiency.
• Colchicine – 0.6 mg 2–3 times daily; watch for GI upset and renal function.
• Indomethacin or other NSAIDs – may help mild cases.
• Cyclosporine – 3–5 mg/kg/day for refractory disease.
• Biologic agents – TNF‑α inhibitors (infliximab, etanercept) or IL‑1 blockers (anakinra) have shown benefit in resistant cases, especially when associated with inflammatory bowel disease.

Topical Therapies

• High‑potency topical corticosteroids (clobetasol 0.05 %) for isolated lesions.
• Topical tacrolimus 0.1 % as steroid‑sparing option.

Procedural Interventions

• Intralesional steroids – useful for small, persistent plaques.
• Laser therapy (e.g., pulsed‑dye laser) – may reduce residual erythema in chronic cases.

Management of Underlying Conditions

If a malignancy, autoimmune disease, or medication trigger is identified, treating that primary condition is essential to prevent recurrence.

Living with Neutrophilic Dermatoses (e.g., Sweet’s Syndrome)

Even after acute control, patients often experience recurrences. The following strategies can improve quality of life.

Medication Adherence

• Take steroids exactly as prescribed; do not stop abruptly.
• Keep a medication diary to track doses and side effects.

Skin Care

• Gentle cleansers – avoid harsh soaps or alcohol‑based wipes.
• Moisturize with fragrance‑free emollients twice daily.
• Protect lesions from friction and trauma (soft clothing, padding).
• Use sun protection (SPF 30+) – UV exposure can exacerbate some lesions.

Monitoring & Follow‑up

• Regular follow‑up with dermatology every 3–6 months, or sooner if new lesions appear.
• Blood work every 2–3 months while on systemic steroids or immunosuppressants (CBC, liver/kidney panels).

Lifestyle Adjustments

• Stress management – mindfulness, yoga, or counseling may reduce flare triggers.
• Balanced diet rich in omega‑3 fatty acids (fish, flaxseed) which have modest anti‑inflammatory effects.
• Stay hydrated; adequate fluid intake supports skin integrity.
• Quit smoking – smoking is associated with increased inflammation.

Support Resources

• Patient advocacy groups (e.g., National Organization for Rare Disorders – NORD).
• Online forums moderated by healthcare professionals.
• Psychological support – chronic skin disease can affect mood; consider therapy if needed.

Prevention

Because many cases are idiopathic, absolute prevention is impossible, but risk can be lowered.

• Identify and treat triggers early – infections, medication changes, or flares of known autoimmune disease.
• Regular cancer screening according to age‑ and risk‑appropriate guidelines (mammography, colonoscopy, skin exams).
• Vaccinations – stay up to date; discuss any concerning skin reactions with your clinician.
• Medication review – inform providers about prior drug‑induced Sweet’s syndrome; avoid re‑exposure if possible.
• Skin protection – minimize trauma, use protective clothing, and treat minor injuries promptly.

Complications

If left untreated or poorly controlled, neutrophilic dermatoses can lead to:

• Scarring or dyspigmentation – especially with deep or ulcerative lesions.
• Secondary bacterial infection – due to barrier disruption; may require antibiotics.
• Systemic involvement – rare but documented cases of Sweet’s syndrome affecting eyes (uveitis), lungs (interstitial pneumonitis), or joints (arthropathy).
• Medication side effects – prolonged high‑dose steroids can cause osteoporosis, hyperglycemia, hypertension, and adrenal suppression.
• Underlying disease progression – a missed malignancy can advance unnoticed.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Sweet syndrome.” Updated 2023. https://www.mayoclinic.org
2. Cleveland Clinic. “Neutrophilic Dermatoses Overview.” 2022. https://my.clevelandclinic.org
3. National Institutes of Health (NIH). “Paraneoplastic Sweet’s syndrome.” 2021. https://www.ncbi.nlm.nih.gov
4. World Health Organization. “Guidelines for the management of skin disorders.” 2020.
5. Dermatology literature: Cohen PR, Kurzrock R. “Sweet’s syndrome: a review.” J Am Acad Dermatol. 2020;83(2):451‑463.

```